PROTOCOL REVIEW AND MONITORING SYSTEM The UMCCC maintains two multidisciplinary committees for protocol review;the Protocol Review Committee (PRC) and the Cancer Prevention and Control PRC (CPC PRC). The objectives of the committees are: (1) To provide peer review of the scientific merit of all clinical trial research to be conducted at the University of Michigan Comprehensive Cancer Center (UMCCC) (2) To define priorities for the use of the Cancer Center resources (Clinical Trials Office, Cancer Center cores, space and patients) (3) To improve the overall quality of clinical research throughout the Cancer Center (4) To provide operational oversight to ensure sufficient scientific progress of supported protocols The PRC reviews all cancer-related therapeutic (including Phase I) clinical research protocols which use cancer center resources. This review is mandatory before submission to the institutional IRB. Additionally, correlative or imaging studies that involve informed consent and include Cancer Center patients are subject to committee review. Cancer control studies, prevention studies, health research and quality of life trials without a therapy component and other similar research protocols are reviewed by the CPC-PRC. Protocols that have been previously peer reviewed by recognized peer-review bodies are exempt from the scientific review by the full committee, but are administratively reviewed by the chair of the PRC or his/her designee. All new clinical research protocols and non-administrative amendments to active, previously approved trials are reviewed by the PRC. Studies not requiring review by the PRC and potentially eligible for review by the CPC-PRC include the following: (1) Studies without a treatment component (i.e. surveys, focus group trials, HRQOL trials). (2) Cancer prevention studies in non-cancer patients (3) Cancer control studies The UMCCC Protocol Review and Monitoring system adheres to all NIH, FDA and University of Michigan guidelines for the conduct of clinical research.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA046592-23
Application #
8147778
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2010-06-01
Budget End
2011-05-31
Support Year
23
Fiscal Year
2010
Total Cost
$156,959
Indirect Cost
Name
University of Michigan Ann Arbor
Department
Type
DUNS #
073133571
City
Ann Arbor
State
MI
Country
United States
Zip Code
48109
Mendiratta-Lala, Mishal; Gu, Everett; Owen, Dawn et al. (2018) Imaging Findings Within the First 12 Months of Hepatocellular Carcinoma Treated With Stereotactic Body Radiation Therapy. Int J Radiat Oncol Biol Phys 102:1063-1069
Cilliers, Cornelius; Menezes, Bruna; Nessler, Ian et al. (2018) Improved Tumor Penetration and Single-Cell Targeting of Antibody-Drug Conjugates Increases Anticancer Efficacy and Host Survival. Cancer Res 78:758-768
Lorenz, Daniel A; Vander Roest, Steve; Larsen, Martha J et al. (2018) Development and Implementation of an HTS-Compatible Assay for the Discovery of Selective Small-Molecule Ligands for Pre-microRNAs. SLAS Discov 23:47-54
Zhou, Bing; Hu, Jiantao; Xu, Fuming et al. (2018) Discovery of a Small-Molecule Degrader of Bromodomain and Extra-Terminal (BET) Proteins with Picomolar Cellular Potencies and Capable of Achieving Tumor Regression. J Med Chem 61:462-481
Cho, Chun-Seok; Park, Hwan-Woo; Ho, Allison et al. (2018) Lipotoxicity induces hepatic protein inclusions through TANK binding kinase 1-mediated p62/sequestosome 1 phosphorylation. Hepatology 68:1331-1346
Chockley, Peter J; Chen, Jun; Chen, Guoan et al. (2018) Epithelial-mesenchymal transition leads to NK cell-mediated metastasis-specific immunosurveillance in lung cancer. J Clin Invest 128:1384-1396
Hertz, Daniel L; Kidwell, Kelley M; Vangipuram, Kiran et al. (2018) Paclitaxel Plasma Concentration after the First Infusion Predicts Treatment-Limiting Peripheral Neuropathy. Clin Cancer Res 24:3602-3610
Parsels, Leslie A; Karnak, David; Parsels, Joshua D et al. (2018) PARP1 Trapping and DNA Replication Stress Enhance Radiosensitization with Combined WEE1 and PARP Inhibitors. Mol Cancer Res 16:222-232
Menghrajani, Kamal; Boonstra, Philip S; Mercer, Jessica A et al. (2018) Predictive models for splenic response to JAK-inhibitor therapy in patients with myelofibrosis. Leuk Lymphoma :1-7
Xiong, Xiufang; Liu, Xia; Li, Haomin et al. (2018) Ribosomal protein S27-like regulates autophagy via the ?-TrCP-DEPTOR-mTORC1 axis. Cell Death Dis 9:1131

Showing the most recent 10 out of 1493 publications